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Although caspase-2 is believed to be involved in death
receptor-mediated apoptosis, the exact function, mode of
activation, and regulation of caspase-2 remain unknown.
Here we show that protein kinase (PK) CK2 phosphory-
lates procaspase-2 directly at serine-157. When intracel-
lular PKCK2 activity is low or downregulated by specific
inhibitors, procaspase-2 is dephosphorylated, dimerized,
and activated in a PIDDosome-independent manner. The
activated caspase-2 then processes procaspase-8 mono-
mers between the large and small subunits, thereby prim-
ing cancer cells for TNF-related apoptosis-inducing ligand
(TRAIL)-mediated apoptosis. The processed procaspase-8
that is recruited to death-inducing signaling complex by
TRAIL engagement becomes fully activated, and cancer
cells undergo apoptosis. PKCK2 activity is low in TRAIL-
sensitive cancer cell lines but high in TRAIL-resistant
cancer cell lines. Thus, downregulating PKCK2 activity is
required for TRAIL-mediated apoptosis to occur in TRAIL-
resistant cancer cells. Our data provide novel insights into
the regulation, mode of activation, and function of cas-
pase-2 in TRAIL-mediated apoptosis.
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Introduction
Caspases are cysteine–aspartate proteases that play critical
roles in the initiation and execution of apoptosis. Caspases
exist as zymogens that contain a prodomain and a protease
domain (Nicholson, 1999). They can be divided into initiator
and effector caspases based on the presence of a large prodo-
main at their N-terminal region (Salvesen and Dixit, 1999).
Initiator caspases that have long prodomains are activated with
the help of adaptor molecules that bring these procaspases into
close proximity, permitting autoprocessing (Fesik, 2000).
Caspases with short prodomains are downstream effector
caspases. Full processing and activation of these caspases
depend on the upstream initiator caspases (Nicholson, 1999).
Caspase-2, one of the initiator caspases, has not been
extensively studied, perhaps because caspase-2-deficient
mice showed only subtle phenotypes (Bergeron et al, 1998;
O’Reilly et al, 2002). Previous reports demonstrated that
caspase-2 is required in stress-mediated apoptosis (Lassus
et al, 2002) or in death receptor-mediated apoptosis (Duan
and Dixit, 1997; Droin et al, 2001; Wagner et al, 2004).
However, the exact function, mode of activation, and regula-
tion of caspase-2 remain unknown.
TNF-related apoptosis-inducing ligand (TRAIL) is a pro-
mising cancer-specific therapeutic agent since it induces
apoptosis in cancer cells but not in most normal cells or
tissues (Ashkenazi et al, 1999; Walczak et al, 1999). One
potential obstacle that may limit the clinical efficacy of TRAIL
is the development of a TRAIL resistance phenotype in many
cancer cells (Zhang et al, 1999; Kim et al, 2000). Specific
protein kinase CK2 (PKCK2, formerly know as casein kinase
2) inhibitors have been successful at sensitizing TRAIL-
resistant cancer cells to TRAIL, but the mechanism of sensi-
tization remains controversial (Ravi and Bedi, 2002;
Izeradjene et al, 2004, 2005). PKCK2 is a constitutively active,
growth factor-independent serine/threonine protein kinase
(Litchfield et al, 1994) composed of two catalytic a (and/or
a0) subunits and two regulatory b subunits (Xu et al, 1999). It
plays a key role in cell cycle control, cellular differentiation,
and proliferation and also participates in the regulation of
apoptosis by phosphorylating some apoptosis-related factors
(Luscher et al, 1989; Allende and Allende, 1995; McElhinny
et al, 1996; Wang et al, 2000; Keller et al, 2001; Li et al, 2002).
In an effort to elucidate the mechanism by which PKCK2
inhibition sensitizes TRAIL-resistant cancer cells to TRAIL,
we found that procaspase-2 is activated by PKCK2 inhibition.
The present study was therefore undertaken to examine
whether the activation of procaspase-2 is regulated by
PKCK2-mediated phosphorylation, to test whether caspase-2
is required to sensitize cancer cells to TRAIL, and to inves-
tigate the function of activated caspase-2 in TRAIL-mediated
apoptosis. We show here that PKCK2 activity is high in
TRAIL-resistant cancer cell lines but low in TRAIL-sensitive
cancer cell lines and that PKCK2 phosphorylates procaspase-
2 at serine-157. When PKCK2 is downregulated, procaspase-2
is dephosphorylated at serine-157. This causes procaspase-2
to dimerize and become activated in a PIDDosome-indepen-
dent manner. The activated caspase-2 then processes procas-
pase-8 monomers between the large and small subunits.
Once the processed procaspase-8 is present in the cell, the
cancer cells are primed for TRAIL-mediated apoptosis.
Results
PKCK2 determines TRAIL sensitivity
Because specific PKCK2 inhibitors sensitized TRAIL-resistant
cancer cells to TRAIL (Ravi and Bedi, 2002; Izeradjene et al,
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2004), we hypothesized that TRAIL sensitivity of cancer cells
is determined by intracellular PKCK2 activity and we ana-
lyzed intracellular PKCK2 activity in cancer cell lines.
Consistent with our assumption, PKCK2 activity is low in the
TRAIL-sensitive cancer cell lines but high in the TRAIL-resis-
tant cell lines (Figure 1A and B and Supplementary Figure 1).
5,6-Dichloro-1-b-D-ribofuranosyl benzimidazole (DRB), a spe-
cific PKCK2 inhibitor, sensitized all the TRAIL-resistant cancer
cell lines to TRAIL (Figure 1A). To further confirm our
hypothesis, siRNA SMART Pools was used to silence endo-
genous PKCK2a in TRAIL-resistant HCE4. When PKCK2a was
silenced (Figure 1C, lanes 1–4, and Supplementary Figure 2),
the cells were killed by TRAIL alone (Figure 1C). To test the
effect of increased PKCK2 activity on TRAIL sensitivity,
PKCK2a was exogenously overexpressed in TRAIL-sensitive
TE2 cells (Figure 1D, lanes 3 and 4). This led to an increase
in PKCK2 activity, and the cells became resistant to TRAIL
(Figure 1D). Therefore, we conclude that the degree of PKCK2
activity determines TRAIL sensitivity.
PKCK2 inhibits procaspase-2 activation
by phosphorylation
To examine whether the activity of caspases is changed by
treatment with DRB and/or TRAIL, colorimetric caspase
activity assays were performed using HCE4 cells. Caspase-2,
-3, -8, and -9 were activated in the presence of both DRB and
TRAIL, but none of them were activated by TRAIL treatment
alone (Figure 2A, left). It was noted that DRB alone induced
caspase-2 activation without inducing cell death (Figure 2A,
left, and Figure 1A). This result was confirmed using in vivo
labeling of active caspases with biotin-VAD-fmk (Figure 2A,
right). These results suggest that PKCK2-mediated phosphor-
ylation may inhibit the activation of procaspase-2. To confirm
this, HCE4 cells were treated with DRB in the presence or
absence of okadaic acid (OA), a protein phosphatase PP-1
and PP-2A inhibitor. Procaspase-2 was phosphorylated at
serine residue(s) (Figure 2B, bottom, lane 1), and DRB
caused it to become dephosphorylated (Figure 2B, bottom,
lane 2) indicating that PKCK2 is the kinase for procaspase-2.
Dephosphorylation of procaspase-2 was not observed when
the cells had been pretreated with OA (Figure 2B, bottom,
lane 4 versus 2), suggesting the involvement of OA-sensitive
phosphatase(s) for dephosphorylation of procaspase-2. When
dephosphorylated, procaspase-2 is cleaved and activated;
however, when OA pretreatment is used to maintain phos-
phorylation, procaspase-2 activation is prevented (Figure 2B,
top). In addition, when PKCK2a was silenced, procaspase-2
was processed and activated even in the absence of both DRB
Figure 1 PKCK2 determines TRAIL sensitivity. (A) TRAIL cytotoxicity toward cancer cells. Cell viability was evaluated by the MTTassay using
cancer cells incubated with or without DRB for 24 h and then subsequently treated with TRAIL for 2 h. The data are expressed as mean7s.d.
for triplicate, and similar results were obtained from two independent experiments. (B) Endogenous PKCK2 activity in cancer cell lines.
(C) Silencing of PKCK2a sensitizes cells to TRAIL. TRAIL-resistant HCE4 cells were transfected with scrambled siRNA (S) or PKCK2a SMART
Pools siRNAs (K) for 48 h and subsequently treated with DRB and/or TRAIL. Western blotting and cell viability assay were performed. PKCK2
activity and caspase-2 activity assays were performed using the siRNA-transfected cells. Relative caspase-2 activity, compared to the scrambled
siRNA-transfected HCE4 cells, was calculated. (D) Acquisition of TRAIL resistance by exogenous PKCK2a expression. TRAIL-sensitive TE2 cells
were transfected with an empty vector (CK2) or with a PKCK2a expression vector (CK2þ ) for 24 h and subsequently incubated with TRAIL
for 2 h. Western blotting and cell viability assay were performed. PKCK2 activity and caspase-2 activity assays were performed using TE2 cells
transfected with an empty vector () or with the PKCK2a expression vector (þ ) for 24 h.
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and TRAIL in TRAIL-resistant HCE4 cells (Figure 1C). When
PKCK2a was overexpressed, procaspase-2 was not processed
and activated, even in the presence of TRAIL in TRAIL-
sensitive TE2 cells (Figure 1D). Consistent with this, there
was an inverse correlation between the intracellular PKCK2
activity and the caspase-2 activity in the cancer cell lines
(Figure 2C versus Figure 1B). To test whether PKCK2 and
procaspase-2 interact directly, HCE4 cells were transfected
with an empty vector or HA-tagged wild-type procaspase-2
and their lysates were mixed with active human recombinant
PKCK2. Western blotting revealed that PKCK2 co-immuno-
precipitated with procaspase-2 in vitro (Figure 2D, top) and
the interaction was confirmed in vivo (Figure 2D, bottom).
Taken together, these results indicate that PKCK2 inhibits
procaspase-2 activation by direct phosphorylation.
PKCK2 phosphorylates procaspase-2 at serine-157
Two potential serine phosphorylation sites were identified in
a tryptic digest of procaspase-2 (Figure 3A, top). To determine
which serine is phosphorylated, procaspase-2 expression
Figure 2 PKCK2 inhibits procaspase-2 activation by direct phosphorylation. (A) Changes in the activity of caspases in DRB- and/or TRAIL-
treated HCE4 cells. (Left) Colorimetric caspase-2, -3, -8, and -9 activity assays were performed using cell extracts of HCE4 cells treated as in
Figure 1A. (Right) In vivo peptide affinity labeling of active caspases was performed as described in Materials and methods. The activation of
caspase-2, -8, or -3 was assessed by Western blotting. (B) PKCK2 inhibition induces dephosphorylation and activation of procaspase-2.
Caspase-2 activity assays were performed using HCE4 cells that had been treated or untreated (control) with DRB (40mM) for 24 h in the
presence or absence of OA pretreatment (1.5 h, 30 nM). The data are presented as relative activity compared to the control and are expressed as
mean7s.d. for triplicate, and similar results were obtained from two independent experiments. Immunoblotting for endogenous procaspase-2
using the same lysates is given below (top). HCE4 cells were treated with z-VAD-fmk (20 mM) and then incubated with DRB (40mM) for 24 h in
the presence or absence of OA (1.5 h pretreatment, 30 nM). Immunoprecipitation (IP) using anti-procaspase-2 antibody (Ab) was followed by
Western blot analysis using anti-phosphoserine Ab. The same blot was reprobed with anti-procaspase-2 Ab (bottom). (C) Endogenous caspase-
2 activity in cancer cell lines. Relative caspase-2 activity compared to HCE4 was calculated. (D) (Top) HCE4 cells were transfected with empty
vectors (V) or HA-tagged wild-type procaspase-2 (wtC2); cell lysates were mixed with active human recombinant PKCK2 (GST-CK2). IP with a
GST- or HA-specific Ab was followed by Western blotting with the indicated Abs. (Bottom) The lysates from the HCE4 cells were
immunoprecipitated with anti-procaspase-2 Ab (C2) or nonimmune IgG (IgG) followed by Western blotting using a PKCK2a-specific Ab.
The same blot was reprobed with anti-procaspase-2 Ab.
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plasmids with various combinations of serine to alanine
mutations were constructed (Figure 3A, top, mtC2-1 to
mtC2-3) and used for transfection. Metabolic labeling and
autoradiography revealed that serine-157 is the phosphoryla-
tion site (Figure 3A, middle; the numbering of residues is
according to Kumar et al, 1997). To examine how dephos-
phorylated procaspase-2 is activated, HCE4 cells were trans-
fected with either a C320A (catalytic cysteine-320 replaced
with alanine) or a nonphosphorylatable S157A/C320A
(serine-157 and cysteine-320 replaced with alanine) mutant
procaspase-2 gene. While the C320A mutant formed a dimer
only when the cells were treated with DRB (Figure 3B, top,
lane 1 versus 2), the nonphosphorylatable S157A/C320A
mutant dimerized constitutively (Figure 3B, top, lanes 3
and 4). These results were confirmed by cotransfecting
HCE4 cells with the following pairs of mutant procaspase-2
genes: an HA-tagged C320A and V5-tagged C320A, an
HA-tagged S157A/C320A and V5-tagged S157A/C320A, or
an HA-tagged C320A and V5-tagged S157A/C320A. Western
blot analysis following IP showed that only dephosphory-
lated procaspase-2 monomers were able to interact with
each other (Figure 3B, bottom). A recent study revealed
that the activation of caspase-2 occurs in the PIDDosome,
a complex containing the death domain-bearing protein
PIDD (p53-induced protein with a death domain) and the
adapter protein RAIDD (Tinel and Tschopp, 2004). To test
whether the dephosphorylation-mediated activation of
procaspase-2 is dependent on the PIDDosome, siRNA was
used to silence the expression of PIDD in HCE4 cells.
Procaspase-2 was processed by PKCK2 inhibition even in
the absence of PIDD (Figure 3C). Therefore, we conclude
that procaspase-2 is activated by dimerization between
dephosphorylated procaspase-2 monomers in a PIDDo-
some-independent manner.
We then examined the effect of a phosphorylation site
mutant procaspase-2 on TRAIL-mediated apoptosis. When
TRAIL-resistant HCE4 cells were transfected with the non-
phosphorylatable S157A mutant procaspase-2 gene, the exo-
genous procaspase-2 was processed and activated even in the
absence of TRAIL (Figure 3D, top), and the cells were killed
by TRAIL in the absence of DRB (Figure 3D, bottom left, lane
3 versus 1). When TRAIL-sensitive TE2 cells were transfected
with an S157E mutant procaspase-2 gene (serine-157 re-
placed with glutamic acid to mimic constitutive phosphoryla-
tion), procaspase-2 was not processed and activated
(Figure 3D, bottom right, lanes 7 and 8), and the cells became
resistant to TRAIL even in the presence of DRB (Figure 3D,
bottom right, lane 8). These results indicate that the S157A
and S157E procaspase-2 mutants act as a dominant active
and a dominant negative procaspase-2 in TRAIL-mediated
apoptosis, respectively. Collectively, the activation of procas-
pase-2 is negatively regulated by PKCK2-mediated phosphor-
ylation at serine-157.
Procaspase-2 activation is a prerequisite
for TRAIL-mediated apoptosis
To determine whether the activation of procaspase-2 by
PKCK2 inhibition is required for TRAIL-mediated apoptosis,
siRNA was used to silence the expression of endogenous
procaspase-2. When procaspase-2 was silenced, DRB could
not sensitize HCE4 cells (Figure 4A, top, lane 4 versus 8) and
LN319 cells (data not shown) to TRAIL. TRAIL-sensitive
SW480 cells became resistant to TRAIL by the silencing of
procaspase-2 as well (Figure 4A, bottom, lane 3 versus 7 and
4 versus 8). To test whether TRAIL-mediated apoptosis
indeed required caspase-2, we attempted to restore sensitivity
to TRAIL by expressing caspase-2 ectopically (Figure 4B). To
prevent the destruction of the ectopic caspase-2 mRNA by the
caspase-2 siRNA, we introduced two silent mutations into the
region of the caspase-2 cDNA that is complementary to the
siRNA (C2sil). Expression of C2sil restored the sensitivity of
TRAIL-resistant HCE4 cells to TRAIL in the presence of DRB
(Figure 4B, lane 2 versus 6), indicating that the effect of the
siRNA (Figure 4A) could be explained by the silencing of
caspase-2. When PKCK2a and procaspase-2 were co-silenced
in HCE4 cells, the cells were not killed by TRAIL (Figure 4C).
To examine whether PKCK2 inhibition also sensitizes normal
cells to TRAIL, human primary normal oral keratinocytes and
HCE4 cells were treated with TRAIL in the presence or
absence of DRB pretreatment. Although procaspase-2 was
processed and activated by DRB in both cells (Figure 4D,
lanes 3 and 7), only HCE4 cells underwent TRAIL-induced
apoptosis (Figure 4D, lane 4 versus 8). In addition, the siRNA-
mediated ablation of caspase-2 expression blocked the ability
of TNF-a (Figure 4E, lane 2 versus 4) or an agonistic anti-FAS
Ab (Figure 4E, lane 6 versus 8) to induce cell death in the
presence of DRB. Therefore, we conclude that PKCK2 acts
upstream of procaspase-2 and that the activation of procas-
pase-2 is a prerequisite for death receptor-mediated apoptosis
to occur in cancer cells but not in normal cells.
Caspase-2 primes cancer cells for TRAIL-mediated
apoptosis by processing procaspase-8
It was previously reported that full activation of caspase-8
requires two sequential cleavage events: the first one sepa-
rates the large and small subunits producing the p43/41 form
and the second one separates the large subunit and the
prodomain (Medema et al, 1997; Chang et al, 2003). When
procaspase-2 was activated by DRB, procaspase-8 was pro-
cessed to its p43/41 form even in the absence of TRAIL
engagement. However, when procaspase-2 was silenced, the
processing was not observed (Figure 4A, lane 6 versus 2),
indicating that caspase-2 processes the procaspase-8 mono-
mer between the large and small subunits. Consistent with
this observation, the processed form of procaspase-8 was
present in TRAIL-sensitive cancer cell lines (Figure 5A,
Procaspase-8, z-VAD-fmk), in which a notable fraction of
the endogenous procaspase-2 pool was activated due to low
intracellular PKCK2 activity (Figure 5A, Procaspase-2, z-VAD-
fmk). These results suggest that caspase-2-mediated
processing of procaspase-8 may prime cancer cells for
TRAIL-mediated apoptosis. To examine whether short-term
inhibition of caspase-2 alters the responsiveness of the
primed cancer cells to TRAIL, TE2 cells were pretreated
with z-VDVAD-fmk, a caspase-2 inhibitor, for 0.5 h before
addition of TRAIL. The processed form of procaspase-8 was
present in the cells at the time of TRAIL engagement
(Figure 5B, bottom, lane 1) and the cells were killed by
TRAIL (Figure 5B). In contrast, in the cells pretreated with
z-VDVAD-fmk for 6 h, the processed form of procaspase-8
was not present (Figure 5B, bottom, lane 3) and the cells
became resistant to TRAIL (Figure 5B). These results suggest
that the processed procaspase-8 in the primed cancer cells
may be rapidly eliminated possibly through the ubiquitin–
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Figure 3 Procaspase-2 is phosphorylated at serine-157. (A) Procaspase-2 is phosphorylated at serine-157. (Top) Schematic representation of
procaspase-2. CARD, caspase recruitment domain; p19 and p12, the large and small subunits that form mature caspase-2. The mutations
introduced into procaspase-2 are highlighted in bold face. (Middle) Extracts of z-VAD-fmk-pretreated HCE4 cells transfected with either an
empty pCMV-HA vector (V), a wild-type procaspase-2 (wtC2) gene, or a mutant procaspase-2 (mtC2-1 to mtC2-3) gene for 24 h and
metabolically labeled for 6 h in the presence of orthophosphate (1 mCi/ml) were immunoprecipitated with anti-HA Ab and subjected to SDS–
PAGE and autoradiography (32P). (Bottom) Comparison of the human procaspase-2 amino-acid sequence (residues 149–168) with mouse, rat,
and dog procaspase-2, showing conservation of serine-157 (boxed). (B) Dimerization of dephosphorylated procaspase-2. (Top) Western
blotting was performed using crosslinked (þDSS, disuccinimidyl suberate) or non-crosslinked (DSS) extracts of HCE4 cells that had been
transfected with the indicated plasmids for 24 h and subsequently incubated with or without DRB for 24 h. (Bottom) HCE4 cells were
cotransfected with the indicated plasmids for 24 h and subsequently incubated with or without DRB for 24 h. IP was then performed using anti-
HA Ab, followed by Western blot analysis with anti-V5 Ab. Western blots of whole-cell lysates confirmed the presence of both HA- and V5-
tagged procaspase-2 in the lysates. (C) PIDDosome-independent activation of procaspase-2. Western blotting was performed using extracts
of HCE4 cells transfected with either scrambled siRNA (S) or PIDD siRNA for 48 h and subsequently treated with or without DRB for 24 h.
(D) Effect of phosphorylation site mutant procaspase-2 on TRAIL-mediated apoptosis. Western blotting was performed using extracts of TRAIL-
resistant HCE4 cells that had been transfected with the indicated plasmids for 24 h (top). Western blotting was performed using extracts of
HCE4 cells (bottom left) or TRAIL-sensitive TE2 cells (bottom right) that had been transfected with the indicated plasmids for 24 h and
subsequently treated with TRAIL in the presence or absence of DRB. ‘Full length’ and ‘CARD’ indicate the full-length procaspase-2 and the HA-
tagged CARD that is generated after activation of procaspase-2, respectively.
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proteasome pathway (Kim et al, 2004a). Indeed, when the
cells were coincubated with proteasome inhibitor MG-132
and z-VDVAD-fmk for 6 h, the processed form of procaspase-8
was detected (Figure 5B, bottom, lane 5 versus 3) and the
cells were killed by TRAIL (Figure 5B). To examine the status
of procaspase-8 in the death-inducing signaling complex
(DISC), HCE4 cells were primed by pretreating with DRB
and then subsequently incubated with z-VDVAD-fmk for 0.5 h
or 6 h. Only the processed form of procaspase-8 was found in
the DISC when the cells were primed by DRB (Figure 5C, top,
lane 2) or when the primed cells were pretreated with z-
VDVAD-fmk for 0.5 h (Figure 5C, top, lane 3). In contrast,
when caspase-2 was inhibited for 6 h in the primed cells, only
the unprocessed procaspase-8 was present in the DISC
(Figure 5C, top, lane 4) as observed in unprimed control
HCE4 cells (Figure 5C, top, lane 1) and the cells became
resistant to TRAIL (Figure 5C, bottom). These results indicate
that TRAIL-mediated apoptosis can occur only in the primed
cells in which the processed form of procaspase-8 is present
at the moment of TRAIL engagement. Therefore, we conclude
that the processing of procaspase-8 between the large and
small subunits by caspase-2 primes cancer cells for TRAIL-
mediated apoptosis, and we define caspase-2 as a ‘priming
caspase’ in TRAIL-mediated apoptosis.
Figure 4 Caspase-2 activation is a prerequisite for TRAIL-mediated apoptosis. (A) Effect of procaspase-2 silencing on TRAIL-mediated
apoptosis. Western blotting was performed using extracts of TRAIL-resistant HCE4 (top) or TRAIL-sensitive SW480 (bottom) cells that
had been transfected with either a scrambled siRNA (S) or procaspase-2 siRNA (2) for 48 h and subsequently treated with TRAIL and/or DRB.
(B) Restoration of sensitivity of HCE4 cells to TRAIL-mediated apoptosis after ectopic expression of caspase-2. Western blotting was performed
using extracts of HCE4 cells cotransfected with either scrambled siRNA (S) and empty vectors (HA), caspase-2 siRNA (2) and empty vectors,
or caspase-2 siRNA and C2sil (HA-C2sil) for 48 h. The cells were subsequently treated with DRB for 24 h and TRAIL (100 ng/ml) for 2 h.
(C) Co-silencing of PKCK2a and procaspase-2. HCE4 cells were transfected with PKCK2a SMART Pools siRNA (K) and/or procaspase-2 siRNA
(2) and then treated with TRAIL and/or DRB. Western blotting (bottom) and cell viability (top) assays were performed. (D) Difference in the
mechanism of TRAIL resistance between human primary normal cells and TRAIL-resistant cancer cells. Human primary normal oral
keratinocytes (left) and HCE4 cells (right) were treated or untreated with DRB for 24 h and subsequently treated with TRAIL for 2 h.
Western blotting was performed using indicated Abs. (E) Caspase-2 is also required in apoptosis that is induced by apoptosis-inducing ligands
other than TRAIL. HCE4 cells were transfected with either scrambled siRNA (S) or caspase-2 siRNA (2) and then treated with TNF-a (Inducer,
T) or an agonistic anti-FAS Ab (Inducer, F) for 2 h in the presence or absence of DRB pretreatment. Western blotting was performed using
indicated Abs.
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Figure 5 Caspase-2 primes cancer cells for TRAIL-mediated apoptosis by processing procaspase-8. (A) Expression level and status of
endogenous procaspase-2 and procaspase-8 in the cancer cell lines. Western blotting was performed using extracts of the cancer cell lines
treated or untreated with z-VAD-fmk. (B) Priming by the presence of processed form of procaspase-8. TRAIL-sensitive TE2 cells were incubated
in the presence or absence of MG-132 (10mM) with z-VDVAD-fmk for 6 h or incubated with z-VDVAD-fmk for 0.5 h and then treated with TRAIL
for an additional 2 h. Cell viability assay (top) and Western blotting (bottom) were performed. (C) Procaspase-8 in the DISC. HCE4 cells were
treated or untreated with DRB for 24 h. The cells were further incubated with z-VDVAD-fmk for the indicated times. DISC IP was performed
followed by Western blotting (top). A cell viability assay was performed in the presence or absence of TRAIL (bottom). (D) Effect of c-FLIP
overexpression on DRB-mediated sensitization of cancer cells to TRAIL. Western blotting was performed using extracts of the cancer cell lines
with indicated Abs (top). HCE4 cells were transduced with c-FLIPL-expressing retroviruses and the cells were treated with or without DRB for
24 h. Western blotting was performed using indicated Abs (bottom left). HCE4 cells were transduced with c-FLIPL-expressing retroviruses and
the cells were treated with TRAIL for 2 h in the presence or absence of DRB pretreatment. Western blotting was performed using indicated Abs
(bottom middle). HCE4 cells were transduced with c-FLIPL-expressing retroviruses and the cells were treated with or without DRB for 24 h.
DISC IP was performed followed by Western blotting using indicated Abs (bottom right).
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Primed cancer cells undergo apoptosis even
in the presence of FLIP overexpression
It has been known that FLICE inhibitory protein (FLIP)
regulates apoptosis by precluding recruitment of caspase-8
to the DISC and thereby prevents its proteolytic cleavage
(Krueger et al, 2001; Rippo et al, 2004). To evaluate the
correlation between FLIP expression and TRAIL sensitivity,
we first checked the expression level of c-FLIP short (c-FLIPS)
and long form (c-FLIPL) in the cell lines. c-FLIPL was
expressed in all the TRAIL-sensitive cell lines and one
TRAIL-resistant cell line (Figure 5D, top, FLIPL). In the case
of c-FLIPS, it was expressed in all of the TRAIL-sensitive cell
lines and two TRAIL-resistant cell lines (Figure 5D, FLIPS).
These results indicate that endogenous FLIP may not be a
determinant of TRAIL sensitivity. We then examined whether
the overexpression of c-FLIPL alters the responsiveness of the
primed cancer cells to TRAIL. When c-FLIPL was over-
expressed, the activation of procaspase-2 (Figure 5D, bottom
left, lane 4; bottom middle, lane 2) and the processing of
procaspase-8 (Figure 5D, bottom, lane 2 versus 4) were still
observed by PKCK2 inhibition, and the cells were also
sensitized to TRAIL (Figure 5D, bottom middle, lane 4). To
examine whether there is a difference in the amounts of
recruited procaspase-8 between the presence and the absence
of c-FLIPL overexpression, DISC IP was performed. We found
that there was no difference in the amount of recruited
procaspase-8 in the DISC, even in the presence of over-
expressed c-FLIPL (Figure 5D, bottom right). These results
suggest that overexpressed FLIP may not act as a negative
modulator of the processed procaspase-8 activation in TRAIL-
induced DISC.
Discussion
Although previous reports showed that caspase-2 is required
in stress-mediated apoptosis (Lassus et al, 2002) or in death
receptor-mediated apoptosis (Duan and Dixit, 1997; Droin
et al, 2001), little is known about the exact function, mode of
activation, and regulation of caspase-2. Our data show that
the activation of procaspase-2 is regulated by PKCK2-
mediated phosphorylation at serine-157, that dephosphory-
lated procaspase-2 is activated by dimerization, and that
active caspase-2 cleaves procaspase-8 monomer between
the large and small subunits, thereby priming TRAIL-resistant
cancer cells for TRAIL-mediated apoptosis. Therefore, we
propose a novel mechanism by which TRAIL-mediated apop-
tosis is regulated (Figure 6).
Recent studies have shown that formation of a stable
dimeric intermediate induces procaspase-8 activation by in-
tramolecular processing between the large and small subu-
nits. This is the first step in the cleavage of procaspase-8 after
dimer formation and renders the region between the large
subunit and prodomain susceptible to further cleavage (Chen
et al, 2002; Boatright et al, 2003; Chang et al, 2003). However,
caspase-8 activation is inefficient in the dimer when intra-
molecular processing between the large and small subunits
does not occur (Chen et al, 2002; Chang et al, 2003). Consis-
tent with this, procaspase-8 was not activated by DISC-
mediated dimerization in TRAIL-resistant cancer cells, in
which PKCK2 activity is high (Figure 5C, top, lane 1 versus 2).
A recent study revealed that activation of procaspase-2
occurs in the PIDDosome (Tinel and Tschopp, 2004).
However, we found that the dephosphorylation-mediated
dimerization and activation of procaspase-2 can occur in
the absence of PIDD (Figure 3C). It is possible that
PIDDosome-dependent caspase-2 activation may operate
only in p53-dependent genotoxic stress-mediated apoptosis.
It is notable that the sequence around serine-157 is highly
conserved between human, mouse, rat, and dog procaspase-2
(Figure 3A, bottom). However, this conservation is not ob-
served in chicken (data not shown), suggesting that the
regulatory mechanism of procaspase-2 activation by PKCK2
may operate only in mammals.
PKCK2 activity is invariably elevated in tumors but not in
normal tissues (Gapany et al, 1995; Faust et al, 1996; Ahmed
et al, 2000), and normal cells are resistant to TRAIL
(Ashkenazi et al, 1999; Walczak et al, 1999). When we
examined whether normal primary epithelial cells can be
sensitized to TRAIL by DRB, we found that procaspase-2 was
activated in both cells, but the processing of procaspase-8 and
apoptotic cell death were observed only in TRAIL-resistant
cancer cells (Figure 4D). Accordingly, we speculate that
primary normal cells or normal cells in tissues are resistant
to TRAIL because they may develop a mechanism(s) by
which activated caspase-2 cannot recognize and cleave
procaspase-8. This could be the reason(s) why caspase-
2-deficient mice have only a few abnormalities (Bergeron
et al, 1998). It is possible that the overt phenotypes of
caspase-2 deficiency can be observed only in certain patho-
logic condition(s), such as cancer.
PKCK2 inhibition by DRB also sensitized cancer cells to
TNF-a or agonistic anti-FAS Ab-mediated apoptosis, but the
silencing of procaspase-2 expression blocked the ability of
TNF-a or an agonistic anti-FAS Ab to induce cell death even in
the presence of DRB (Figure 4E). These results suggest that
the priming of procaspase-8 by caspase-2-mediated proces-
sing is a general mechanism for death receptor-mediated
apoptosis. In addition, it has been reported that the combined
use of a DNA-damaging cancer chemotherapeutic and TRAIL
synergistically kill TRAIL-resistant cancer cells (Lacour et al,
2001), and that cytotoxic stress such as DNA damage induces
cell death through procaspase-2 activation (Lassus et al,
2002). When we checked PKCK2 activity after cytotoxic
stress, PKCK2 activity was downregulated and procaspase-2
was activated by etoposide or cisplatin treatment (unpub-
lished observation). Therefore, PKCK2-regulated procaspase-
2 activation plays a central role in both death receptor-
mediated and stress-mediated apoptosis.
In summary, we have shown the novel mechanism by
which caspase-2 activation is regulated, and the role of
caspase-2 in TRAIL-mediated apoptosis.
Materials and methods
Cell lines and culture conditions
The human esophageal cancer cell lines (TE2, HCE4, and HCE7)
and human colon cancer cell lines (SW480 and HCT116) were
grown as previously described (Kim et al, 2000). The human
malignant glioma cell line LN319 was cultured at 371C in DMEM
containing 10% fetal bovine serum, 100 U/ml penicillin, and 100 mg/
ml streptomycin. Human primary normal oral keratinocytes were
kindly provided by Dr Jongin Yook (Yonsei University College of
Dentistry). The keratinocytes were grown in Keratinocyte-SFM
medium (Gibco BRL, Rockville, MD) containing bovine pituitary
extract (40mg/ml) and epidermal growth factor (1 ng/ml). The cells
were treated for 2 h with either 100 ng/ml TRAIL (Kim et al, 2004b),
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35 ng/ml TNF-a (Sigma-Aldrich Co., St Louis, MO), or 50 ng/ml of
an agonistic anti-FAS Ab (clone CH11; Upstate Biotechnology, Lake
Placid, NY). OA, a protein phosphatase PP-1 and PP-2A inhibitor,
was purchased from Sigma-Aldrich. Cells were pretreated with OA
for 1.5 h at a final concentration of 30 nM. Inhibition of PKCK2 was
achieved by incubating the cells with DRB (Calbiochem, La Jolla,
CA) for 24 h at a final concentration of 40 mM (Zandomeni, 1989).
The irreversible pan-caspase inhibitor, z-VAD-fmk (R&D Systems,
Minneapolis, MN), was used at a final concentration of 20 mM.
Biotin-VAD-fmk was purchased from Calbiochem. The caspase-2
inhibitor, z-VDVAD-fmk, was purchased from R&D Systems and
used at a 20mM concentration. MG-132, a proteasome inhibitor, was
purchased from Calbiochem. DSS (5 mM; Pierce, Rockford, IL) was
used to crosslink interacting proteins and to maintain the crosslinks
under the reducing conditions of SDS–PAGE.
siRNAs
siRNAs were purchased from Dharmacon Inc. (Option A4;
Lafayette, CO). The target sequences for caspase-2 (Lassus et al,
2002) and PIDD (Tinel and Tschopp, 2004) were previously
described. Dharmacon SMART Pools siRNAs were used for
silencing PKCK2a. A scrambled siRNA was used as a control.
Site-directed mutagenesis
To introduce silent mutations into the regions of the procaspase-2
cDNA that are cognate to the corresponding siRNA, the nucleotide
pair GC in positions 161–162 of the procaspase-2 gene was mutated
into AT (C2sil) (Lassus et al, 2002) using a Quick change site-
directed mutagenesis kit (Stratagene, La Jolla, CA). Potential
serine phosphorylation sites in wild-type procaspase-2 were also
mutagenized into alanine as shown in Figure 3A.
cDNAs
Wild-type or mutant procaspase-2 cDNAs were cloned into either
pCMV-HA (Clonetech, Palo Alto, CA) or pcDNA3.1/V5-His (In-
vitrogen, Carlsbad, CA). PIDD and PKCK2a cDNAs were cloned into
pcDNA3.1/V5-His.
Transfection
Cells were transfected with the siRNAs and/or plasmids using either
Lipofectamine 2000 (Invitrogen) or Nucleofector (AMAXA,
Gaithersburg, MD, Program A-28) according to the manufacturers’
protocol.
Cell viability assay
Cell viability was measured using the MTT assay (Kim et al, 2000).
The data are expressed as mean7s.d. for triplicate, and similar
results were obtained from two independent experiments.
Western blot immunostaining
Western blot analysis was performed as previously described (Kim
et al, 2000). The cell lysates were prepared by directly adding
1 SDS sample loading buffer to the cells followed by 15 bursts of
sonication (cycle 0.5, amplitude 80%) and boiling at 1001C for
5 min. The blotted membranes were immunostained with Abs
specific for the following antigens: phosphoserine (Zymed Labora-
tories Inc., South San Francisco, CA), caspase-2 (BD Transduction
Laboratories, San Jose, CA and Delta Biolabs, Campbell, CA),
caspase-3 (Santa Cruz Biotechnology Inc., Santa Cruz, CA),
caspase-8 (Cell Signaling Technology Inc., Beverly, MA), Bid (Cell
Signaling Technology), Fas-associated death domain protein (FADD;
Upstate Biotechnology, Lake Placid, NY), FLICE-like inhibitory
protein (FLIPL; Alexis Biochemicals, San Diego, CA), FLIPS
(Calbiochem), PIDD (Alexis Biochemicals), poly ADP-ribose poly-
merase (PARP; Cell Signaling Technology Inc.), PKCK2a (Upstate
Figure 6 Proposed mechanism by which TRAIL-mediated apoptosis is regulated. (Left) When intracellular PKCK2 activity is low ( ) or when
high intracellular PKCK2 activity is downregulated by a specific inhibitor ( ), dephosphorylated procaspase-2 monomers form dimers.
Procaspase-2 is then activated through the dimerization ( ), and activated caspase-2 cleaves procaspase-8 monomer between the large and
small subunits ( ). At this point, the cancer cells are ‘primed’ for TRAIL-mediated apoptosis. If TRAIL is not bound to the TRAIL-death
receptor(s), the cleaved procaspase-8 goes to the proteasome for degradation ( ). On the other hand, if TRAIL is bound to its receptor, the
cleaved procaspase-8 is recruited to the TRAIL death receptor(s), thereby forming DISC ( ). The second cleavage between the prodomain and
large subunit could occur efficiently by DISC-mediated dimerization of the cleaved procaspase-8 ( ), which leads to the activation of
procaspase-8 ( ), and TRAIL-mediated apoptosis ( ). (Right) When intracellular PKCK2 activity is high, procaspase-2 cannot be activated;
thus, procaspase-8 cannot be processed. Even with the engagement of TRAIL, procaspase-8 in the DISC cannot be fully activated, and thus,
TRAIL-mediated apoptosis cannot occur.
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Biotechnology), HA (Covance, Berkeley, CA), V5 (Abcam Inc.,
Cambridge, MA), GST (Santa Cruz Biotechnology Inc.), and
a-tubulin (Oncogene Science, Cambridge, MA).
Caspase activity assays
Activity of caspase-2, -3, -8, or -9 was detected using colorimetric
assay kits (R&D Systems). The data are expressed as mean7s.d. for
triplicate, and similar results were obtained from two independent
experiments.
PKCK2 activity assay
PKCK2 activity was measured using a Casein Kinase-2 Assay Kit
(Upstate Biotechnology). A recombinant full-length human PKCK2
protein that contains an a-subunit N-terminal 6xHis tag and a
b-subunit N-terminal GST tag (Upstate Biotechnology) was used
as a positive control.
Immunoprecipitation
Cells were collected and lysed in 1 ml IP lysis buffer (50 mM Tris, pH
7.4, 150 mM NaCl, and 0.5% NP-40) with 1 protease inhibitor
cocktail (Roche Diagnostics). The cell lysates were precleared and
then incubated with the indicated Abs for 1 h at 41C. The complexes
were precipitated with Protein A/G-Sepharose beads (Santa Cruz
Biotechnology Inc.), washed, and resuspended in 40ml 1 SDS
sample buffer. Nonimmune mouse IgG (Santa Cruz Biotechnology
Inc.) served as a negative control.
Retrovirus production and viral transduction
FLIPL was cloned into pBABE-puro. An amphotropic retroviral
packaging cell line, fNX-ampho, was transfected with the plasmid.
At 48 h after transfection, the supernatant was collected. The
supernatant with polybrene added (800mg/ml) was used to infect
HCE4 cells. At 48 h after infection, the cells were used for
experiments.
DISC IP
To perform DISC IP, cells were grown, harvested, and resuspended
in 2 ml of DMEM (1.5107 cells/ml). TRAIL (500 ng/ml) was added
to the resuspended cells. The cells were treated with TRAIL for
10 min at 371C in a water bath with intermittent agitation. TRAIL
treatment was stopped by adding 5 ml of ice-cold PBS, followed by
immediate centrifugation. After washing once more with 2 ml of ice-
cold PBS, the cells were lysed with IP lysis buffer with 1 protease
inhibitor cocktail for 30 min on ice. The cell lysates were cleared by
centrifugation (15 000 r.p.m. 15 min 2) at 41C. IP was then
performed with anti-His Ab (R&D systems).
In vivo labeling of active caspases
To label the active site of caspases, 1107 cells were incubated for
1 h with 10mM biotin-VAD-fmk following apoptosis induction. Cells
were collected and lysed in 1 ml of IP lysis buffer with 1 protease
inhibitor cocktail. The biotinylated proteins were captured using
30ml of streptavidin-conjugated agarose beads (Calbiochem). After
overnight rotation at 41C, the agarose beads were extensively
washed in lysis buffer containing 0.5% Nonidet P-40. The
biotinylated proteins were eluted from the beads by the addition
of 60 ml of 1 SDS sample loading buffer and incubation at 951C for
10 min. The blotted membranes were immunostained with Abs
specific for caspases.
Supplementary data
Supplementary data are available at The EMBO Journal Online.
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